BrickBio, a company specializing in site-specific bioconjugation for improved therapeutics, has signed an agreement with a large pharmaceutical company to co-develop a therapeutic antibody drug conjugate (ADC). Additional details were not disclosed.

BrickBio focuses in the areas of oncology, neurology, and metabolic disease, although the company's site-specific modification process is expandable beyond the scope of these disease areas. In addition to expanding its internal pipeline, the company has entered into a number of partnerships with top pharmaceutical companies and international partners within one year of the company moving into its lab space.

"The growing number of partnerships that BrickBio has established with pharmaceutical companies speaks measures to the power of the BrickBio platform technology to not only improve key therapeutic characteristics of existing molecules, but also to create new classes of molecules, ultimately increasing the number of available treatment options for patients," stated Audrey Warner, Head of Business Development at BrickBio and Vice President of Investments at Tiger Gene. "BrickBio is excited about the significant potential of its current partnerships with pharmaceutical companies and will continue to expand its deal pipeline in the antibody drug conjugate (ADC) and protein therapeutic market," Warner concluded.